Acasti Pharma (NASDAQ:ACST) Research Coverage Started at HC Wainwright

Investment analysts at HC Wainwright started coverage on shares of Acasti Pharma (NASDAQ:ACST) in a note issued to investors on Wednesday, June 26th, Marketbeat.com reports. The firm set a “buy” rating and a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 279.75% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research downgraded Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. ValuEngine raised WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $5.25.

NASDAQ:ACST traded up $0.21 during mid-day trading on Wednesday, hitting $1.58. 5,045,506 shares of the company’s stock traded hands, compared to its average volume of 541,337. The company has a market cap of $110.71 million, a P/E ratio of -2.23 and a beta of 1.15. The stock has a fifty day moving average of $1.12. Acasti Pharma has a twelve month low of $0.43 and a twelve month high of $1.80.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pura Vida Investments LLC purchased a new stake in Acasti Pharma during the 4th quarter worth about $157,000. Geode Capital Management LLC purchased a new stake in shares of Acasti Pharma in the 4th quarter valued at about $40,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Acasti Pharma in the 4th quarter valued at about $1,480,000. 3.12% of the stock is owned by institutional investors.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Featured Story: 52-Week High/Low

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.